Zivo Bioscience, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OID
ZIVO Bioscience reported increased product revenue for Q3 2025, but continued to face significant operating losses and a going concern warning, necessitating further capital raises.
OID
Zivo Bioscience reported a reduced net loss for Q2 2025 but faces substantial doubt about its ability to continue as a going concern due to critically low cash reserves.
OID
Zivo Bioscience's Q1 2025 results reveal a significant net loss and increased R&D spending, alongside concerns about the company's ability to continue as a going concern.
OID
Zivo Bioscience saw a revenue increase in Q3 2024 compared to the same period last year, but the company continues to operate at a loss.
OID
Zivo Bioscience's Q2 2024 results reveal no revenue, increased operating expenses, and a net loss, alongside ongoing efforts to secure additional funding.
OID
Zivo Bioscience reports increased revenue and reduced expenses in Q1 2024, but acknowledges ongoing concerns about its ability to continue as a going concern.